Oric’s stock rallies on multiple myeloma deal with Pfizer


Shares of Oric Pharmaceuticals Inc. soared about 56% in premarket trading on Thursday, the day after the company said it will collaborate with Pfizer Inc. to develop a multiple myeloma therapeutic candidate. Pfizer will pay $4.65 per share for 5,376,344 of Oric’s common shares, for a total of $25 million. The companies plan to move the treatment into a Phase 2 clinical trial in combination with elranatamab, Pfizer’s investigational treatment of multiple myeloma. A Pfizer executive, Jeff Settleman, will also join Oric’s scientific advisory board. Oric said it now has a cash runway into the first half of 2025. Oric’s stock has declined 79.6% so far this year, while the broader S&P 500 is down 18.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleDeep Dive: This company has wiped out more investor wealth in 2022 than Tesla
Next article: These are the China stories to watch in 2023


Please enter your comment!
Please enter your name here